Drug · Adc
Mirvetuximab Soravtansine
CI-DRUG-00000770Explore in graph →CHEMBL3545132 Approved
Regulatory
Approvals (4)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as ELAHERE (DIN 02560771) under ATC L01FX26 MIRVETUXIMAB SORAVTANSINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jan 9, 2026 | health-canada-dpd |
| EU EMA | Malignant Peritoneal Neoplasm | Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. | approved | Nov 14, 2024 | ema |
| US FDA | — | Efficacy supplement 2024-03-22 (see label) | approved | Mar 22, 2024 | openfda |
| US FDA |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 18 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 3 | 13 | 7 | 5 | 25 | 4 | CA, EU, US | Nov 14, 2022 | Jun 28, 2012 |
| Malignant Ovarian Neoplasm | Phase3 | Phase 3 | 5 | 4 | 5 | 13 | 0 | — | — | Mar 2, 2016 |
| Malignant Uterine Corpus Neoplasm | Phase2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Jul 12, 2018 |
| Malignant Breast Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 3 | 0 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (26)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer(FLORENZA) | recruiting | Phase 2 | 400 | AbbVieINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT07825753 | Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer |